TMCnet - World's Largest Communications and Technology Community



Research and Markets: Quad 2 (HIV) - Forecast and Market Analysis to 2022
[April 24, 2013]

Research and Markets: Quad 2 (HIV) - Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets has announced the addition of the "Quad 2 (HIV) - Forecast and Market Analysis to 2022" report to their offering.

GlobalData has released its new PharmaPoint Drug Evaluation report, Quad 2 (HIV) - Forecast and Market Analysis to 2022. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals.

Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling atient compliance.

Quad 2 is a single-pill, complete regimen being developed by Gilead for the treatment of HIV. The drug has a similar formulation to Gilead's Stribild (elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine), except that Quad 2 contains tenofovir alafenamide fumarate (TAF), which is prodrug of tenofovir disoproxil fumarate (TDF (News - Alert)).

TAF, previously referred to as GS-7340, requires a 30-fold-less dose to achieve the same virological effect as TDF (Gilead Sciences, 2012d). The trend towards physician/patient preference for single-pill, complete regimen has resulted in Gilead developing TAF exclusively as a component of a single-tablet regimen, so a standalone formulation of TAF is unlikely to be pursued.


- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Quad 2 including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Quad 2 for the top nine countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for HIV

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Quad 2 performance

- Obtain sales forecast for Quad 2 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

For more information visit Research and Markets

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy